Glossary · Clinical

NSAIDs

NSAIDs (nonsteroidal anti-inflammatory drugs) are a class of medications that reduce pain, inflammation, and fever by inhibiting the cyclooxygenase (COX-1 and COX-2) enzymes. In orthopedics, they are first-line pharmacologic agents for conditions including arthritis, tendinitis, bursitis, and post-operative pain management.

Verified May 8, 2026 · 5 sources ↓

Drawn from NIHOrthoInfoMyArthritisEn

Definition

Source · Editorial summary grounded in 5 cited references ↓

NSAIDs block cyclooxygenase enzymes, which are responsible for producing prostaglandins—the signaling molecules that drive pain and inflammation at injured or arthritic joints. Traditional NSAIDs (ibuprofen, naproxen, nabumetone, aspirin) inhibit both COX-1 and COX-2. COX-1 inhibition disrupts the protective gastric mucosal lining and impairs platelet aggregation, which accounts for the GI bleeding risk and increased bruising seen with long-term use. COX-2 selective inhibitors (e.g., celecoxib) were developed to spare the gastric mucosa while still suppressing joint inflammation, though their cardiovascular risk profile requires careful patient selection.

In orthopedic practice, NSAIDs are used across the full clinical spectrum: acute musculoskeletal injuries, degenerative joint disease, inflammatory arthropathies, peri-operative analgesia, and post-fracture pain. However, evidence suggests that COX inhibition may delay bone healing by suppressing prostaglandin-mediated osteoblast activity. Short-term peri-operative use is generally considered acceptable, but prolonged NSAID use following fracture fixation or spinal fusion remains a point of clinical debate and warrants documentation of medical necessity.

Systemic adverse effects are clinically significant in orthopedic patients, who often skew older and carry comorbidities. Renal prostaglandins maintain afferent arteriolar tone; NSAID-related reduction in prostaglandin levels can precipitate acute kidney injury, particularly in volume-depleted post-surgical patients. Cardiovascular risk—including elevated myocardial infarction and stroke risk—has prompted FDA label updates for both traditional and COX-2 selective agents. GI prophylaxis with a proton pump inhibitor is standard when NSAIDs are prescribed long-term or in patients with prior GI ulceration.

Why it matters

Payers scrutinize NSAID-related claims when the drug code or administration code does not align with a documented inflammatory or pain diagnosis. A mismatch between the ICD-10 diagnosis code on the claim and the documented indication for NSAID therapy is one of the most common triggers for claim denial and post-payment audit in orthopedic and pain management practices. Additionally, prescribing an NSAID in a patient with active renal insufficiency, post-operative volume depletion, or recent cardiovascular event—without documented risk-benefit discussion—creates both clinical liability and documentation gaps that can unravel medical necessity arguments during payer review. For spinal fusion or fracture cases, failure to document the planned NSAID duration and rationale can lead to post-audit recoupment if a payer argues the drug contributed to a non-union that required a subsequent procedure.

Common mistakes

Where people most often go wrong with this concept.

Source · Editorial brief grounded in cited references ↓

Documenting 'pain' as the sole indication without specifying the inflammatory or musculoskeletal diagnosis, causing an ICD-10 mismatch with the NSAID order and triggering claim denial.
Failing to document contraindication screening (renal function, cardiovascular history, GI history) before prescribing, which undermines medical necessity if the claim is audited.
Ordering a COX-2 inhibitor without documenting why the patient could not tolerate a traditional NSAID, since payers often require step therapy evidence before approving the higher-cost selective agent.
Not recording NSAID use in the medication reconciliation note for a peri-operative encounter, leading to undocumented drug interactions or missed anesthesia risk factors that affect the visit level billed.
Prescribing long-term NSAIDs post-fracture or post-fusion without documenting the expected duration and monitoring plan, which can be used by payers to challenge medical necessity of a subsequent revision surgery.
Conflating topical NSAID formulations (e.g., diclofenac gel) with oral systemic NSAIDs in billing documentation, which carry different HCPCS codes and may require separate prior authorization pathways.

Related codes

Codes commonly involved when this concept appears in practice.

CPT

ICD-10

M19.90 M79.3 M70.20

Modifiers

KX Medical-policy requirements met

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 5 cited references ↓

01What is the difference between a traditional NSAID and a COX-2 inhibitor in orthopedic use?

Traditional NSAIDs block both COX-1 and COX-2 enzymes. Blocking COX-1 reduces the stomach's protective mucus layer, raising GI bleeding risk. COX-2 inhibitors selectively target the inflammation-linked enzyme while largely sparing COX-1, which improves GI tolerability but introduces a cardiovascular risk that requires careful patient screening. In orthopedics, COX-2 inhibitors are often prescribed for long-term arthritis management in patients with prior GI complications, provided cardiovascular risk is acceptable.

02Can NSAIDs slow bone healing after fracture or spinal fusion?

Evidence suggests COX inhibition may impair prostaglandin-driven osteoblast activity and delay bone healing. Short-term post-operative NSAID use (typically under two weeks) is generally considered safe, but prolonged use following fracture fixation or spinal fusion remains controversial. Surgeons should document the duration, rationale, and patient counseling in the record, particularly because payers may scrutinize NSAID use if a non-union or failed fusion subsequently requires revision surgery.

03Why would an NSAID-related claim be denied by a payer?

The most common denial triggers are an ICD-10 diagnosis code that does not clearly support an inflammatory or pain indication, absence of step-therapy documentation when a higher-cost COX-2 inhibitor is prescribed, and missing prior authorization for prescription-strength formulations. Ensuring the diagnosis code in the assessment matches the documented reason for the NSAID is the single most effective way to prevent these denials.

04Are there orthopedic patients who should not receive NSAIDs?

Yes. Patients with significantly reduced eGFR (renal insufficiency), active peptic ulcer disease, recent myocardial infarction or stroke, or those on anticoagulation therapy require especially careful risk-benefit evaluation. Post-surgical patients who are volume-depleted are at elevated risk for NSAID-induced acute kidney injury. The clinical decision to use or avoid NSAIDs in these populations should be explicitly documented to support both patient safety and medical necessity in the record.

05How does Mira help document NSAID use for billing purposes?

Mira's AI scribe layer detects NSAID references in the encounter note and prompts the provider to link the medication to a specific, coded musculoskeletal diagnosis, document contraindication screening, and—when a COX-2 inhibitor is chosen—capture the rationale required for step-therapy compliance. This reduces the risk of ICD-10 mismatches and missing documentation that commonly trigger claim denials or post-payment audits.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira AI Scribe

When Mira detects an NSAID order or an NSAID listed in the medication reconciliation section of an orthopedic encounter note, it should prompt the provider to confirm and capture the following documentation elements to support clean claim submission and audit defense: 1. SPECIFIC INDICATION: Link the NSAID to a coded inflammatory or pain diagnosis (e.g., M19.011 primary osteoarthritis, right shoulder; M70.21 olecranon bursitis, right elbow). Generic 'pain' alone is insufficient for payer medical necessity review. 2. DRUG CLASS SELECTION RATIONALE: If a COX-2 inhibitor is chosen, document the reason (e.g., prior GI ulcer, intolerance to traditional NSAIDs, high GI-risk profile). Most payers require step-therapy documentation before approving selective agents. 3. CONTRAINDICATION SCREENING: Record eGFR or creatinine trend if renal risk is present; note cardiovascular history and current antiplatelet or anticoagulant use; document GI history and whether PPI co-prescription was considered. 4. FRACTURE / FUSION CONTEXT: If NSAIDs are prescribed within 90 days of a fracture fixation or spinal arthrodesis, document expected duration (ideally ≤2 weeks short-term) and the clinical rationale for use versus alternative analgesic options. This language protects against payer challenge if a non-union revision claim is later submitted. 5. TOPICAL VS. SYSTEMIC: If a topical NSAID (e.g., diclofenac 1% gel) is prescribed, distinguish it explicitly in the note; topical formulations bill under separate HCPCS codes and may carry distinct prior-authorization requirements. Mira will auto-flag encounters where an NSAID is present in the medication list but no corresponding musculoskeletal or inflammatory ICD-10 code appears in the assessment, reducing denial risk before claim submission.

See Mira's approach

Related terms

Corticosteroid injection Clinical

A corticosteroid injection is an in-office procedure in which a steroid medication—such as triamcinolone acetonide or methylprednisolone acetate—is deposited directly into a joint, bursa, or soft-tissue structure to reduce inflammation and relieve pain. It is billed with a joint-specific CPT code (20600–20611) plus a separate HCPCS drug code for the agent administered.